A Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis Clinical Trial

Official title:

A Study of Phase Ⅰb/II to Evaluate the Safety, Efficacy and Pharmacokinetic Characteristics of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05525715
• Other study ID #: QY201-?-2
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• Start date: October 2022
• Est. completion date: December 2025

Study information

• Verified date: August 2022
• Source: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
• Contact: LiMing Wu, Ph.D, M.D
• Phone: 0571- 56007501
• Email: 18957118053[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase Ib/II, randomized, double-blind, placebo-controlled, parallel, multicenter study of a certain phase to evaluate the efficacy, safety, and pharmacokinetic characteristics of QY201 tablet in subjects in moderate to severe atopic dermatitis

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 260
• Est. completion date: December 2025
• Est. primary completion date: December 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Having been informed the purpose, nature, methods and possible adverse reactions of the trial, the subjects agreed to be subjects and sign an informed consent form before the start of any research process.

2. Part1(Phase ?b):Male and female subjects aged 18 to 65 (including 18 and 45).Part2(Phase ?):Male and female subjects aged 18 to 75 (including 18 and 45).

3. Atopic dermatitis with a diagnosis confirmed by a dermatologist (according to the Hanifin and Rajka criteria); and also onset of symptoms at least 6 month prior to screening visit.

4. Moderate to severe atopic dermatitis defined by an IGA score = 3,an EASI = 16, an PP-NRS=4, and an BSA = 10% at the screening and baseline visit.

5. Documented history (within 6 mouths prior to the screening visit) of inadequate or medically inadvisable response to topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), systematic treatment or phototherapy.

6. Twice daily use of an stable-dose, additive-free, bland emollient for at least 7 days prior to Day 1, and continued for the duration of this trial.

7. Communicate well with investigators, understand and abide by requirements of this trial.

Exclusion Criteria:

1. Have evidence of active or latent or inadequately treated infection with mycobacterium tuberculosis (TB) as defined by investigators or specialist physicians according to history, symptoms, signs, laboratory tests, T-SPOT test,and imagings, unless subjects had previously received an adequate course of therapy at least 1 month.

2. History of mental disorders, genetic history of mental disorder, or epilepsy treated by antipsychotics and sedatives.

3. In addition to AD, subjects who have current or recent history of clinically significant severe immunologic/rheumatologic, cardiovascular, hepatic, renal, gastrointestinal, or neurologic disease, or have a history of malignancies with the exception of adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ that might need systematic hormone therapy or other interventions, may increase the risk defined by investigators.

4. In addition to AD, subjects have other dermatoses that affect the evaluation of trial results, or have a wide range of tattoos, birthmarks, skin scars in the skin lesion area.

5. Have a known immunodeficiency disorder or a first-degree relative with a hereditary immunodeficiency.

6. Subjects who have received or are planning to receive an organ transplant operation and are taking immunosuppressants, such as liver or kidney transplantation.

7. Any of the following abnormalities:

1. Within 3 months, subjects who have acute myocardial infarction, unstable angina pectoris, coronary artery bypass grafting, or coronary stent implantation prior to Day 1;

2. Have a history of severe arrhythmias, such as (Grade II type 2 or III ATV block, long QT syndrome, or QTcF abnormalities: >470 ms in men and >480 ms in women);

3. Decompensated cardiac insufficiency (NYHA Class III or IV);

4. Other cardiac conditions that required treatment and are ineligible for the study according to the investigator.

8. Infected with various viruses. For Hepatitis B, subjects who are Hepatitis B Surface Antigen (HBsAg) or Hepatitis B Core Antibody (HBcAb) positive, and HBV-DNA positive are not eligible for the study. For hepatitis C, subjects who are HCV antibody positive is excluded. Subjects who are Human Immunodeficiency Viruses antibody or Treponema pallidum antibody positive are also not eligible for the study.

9. Presence of any of the following laboratory abnormalities at the screening visit:

1. Part 1 (Phase ?b):

Fasting blood glucose>Upper limit of normal (ULN);Hypertension poorly controlled by medication (Systolic pressure=150mmHg, Diastolic pressure=95mmHg);WBC, Neutrophils, Lymphocyte count, Platelet count or Hemoglobin<lower limits of normal (LLN);Serum creatinine>ULN or eGFR<60 mL/min;Total bilirubin, AST or ALT values>ULN;PT or APTT values>ULN;

2. Part 2 (Phase ?):

Fasting blood glucose poorly controlled>10 mmol/L;Hypertension poorly controlled by medication (Systolic pressure=160mmHg, Diastolic pressure=100mmHg);WBC<3.0×109/L, Neutrophils<1.5×109/L; Lymphocyte count<0.8×109/L, Platelet count<100.0×109/L and Hemoglobin<100 g/L;Serum creatinine>1.5 times the ULN or eGFR<40 mL/min;Total bilirubin>1.5 times the ULN, AST or ALT values>2 times the ULN;PT or APTT values>1.5 times the ULN.

10. Have a clinical symptomatic infection requiring antimicrobial therapy, such as bacteria, viruses, parasites or fungi during screening.

11. Have a history (single episode) of disseminated herpes zoster or disseminated herpes simplex, or a recurrent (more than one episode ) of localized, dermatomal herpes zoster.

12. Have a history of cerebral hemorrhage or cerebral infarction within 1 years prior to Day 1.

13. Have a history of alcohol or substance abuse within 6 months prior to Day 1.

14. Have a history of hemorrhage (more than 400 mL), such as trauma, blood collection or donation, or have a plan of blood donation during or after the study.

15. Have been treated by JAK inhibitors, such as Ruxolitinib, Tofacitinib, Baricitinib, Filgotinib, Lestaurtinib, Pacritinib, Delgocitinib, Upadacitinib, or Abrocitinib, within 3 months prior to Day 1.

16. Have been treated by biologicals of AD, such as Dupilumab, within 8 weeks or 5 half-live prior to Day 1, whichever is longer.

17. Have received grade 3 or 4 surgery within 8 weeks prior to Day 1.

18. Have been vaccinated with live or attenuated live vaccine within 4 weeks prior to Day 1.

19. Prior to Day 1, have joined any clinical trial of drug within 4 weeks (or 5 half-life periods, depending on the longer one), or any clinical trial of medical apparatus and instruments within 3 months.

20. Have been treated by any long-acting anticoagulant drugs, such as Warfarin, Clopidogrel, or subjects who require continuous anticoagulant therapy, except for Aspirin=100 mg per day.

21. Have a history of oral immune suppressants (eg, systemic corticosteroids, cyclosporine A [CsA], mycophenolate-mofetil [MMF], interferon-? [IFN-?], azathioprine, methotrexate) or Phototherapy (eg, UVB or PUVA) within 4 weeks or within 5 half-lives (if known) prior to Day 1, whichever is longer.

22. Have received topical treatments that could affect atopic dermatitis (eg, corticosteroids (TCS), calcineurin inhibitors (TCI), or PDE-4 inhibitors) within 2 weeks prior to Day 1.

23. Have received strong inhibitors or inducers of CYP3A Hepatic metabolic enzymes.

24. Subjects who are unable to take tablets, allergic to the active ingredient or excipient of the investigational drug.

25. In the opinion of the investigator, subjects have a history of gastrointestinal diseases that will affect the absorption of oral drugs, such as gastrointestinal perforation.

26. Pregnant female subjects, breastfeeding female subjects, or male subjects able to father children and female subjects of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 6 months after last use of investigational drug.

27. Subjects who are unavoidable to or plan exposure to natural or artificial ultraviolet (UV) radiation which could affect atopic dermatitis in the opinion of the investigator.

28. In the opinion of the investigator, subjects who are not suitable to participate in this clinical study.

Related Conditions & MeSH terms

• Atopic Dermatitis
• Dermatitis
• Dermatitis, Atopic
• Eczema

Intervention

Drug:
• 2mg QY201 tablets or 2mg QY201 placebo,BID
2mg QY201 tablets or 2mg QY201 placebo,BID
• 5mg QY201 tablets or 5mg QY201 placebo,BID
5mg QY201 tablets or 5mg QY201 placebo,BID
• 10mg QY201 tablets or 10mg QY201 placebo,QD
10mg QY201 tablets or 10mg QY201 placebo,QD
• 10mg QY201 tablets or 10mg QY201 placebo,BID
10mg QY201 tablets or 10mg QY201 placebo,BID
• 15mg QY201 tablets or 15mg QY201 placebo,BID
15mg QY201 tablets or 15mg QY201 placebo,BID
• 20mg QY201 tablets or 20mg QY201 placebo,BID
20mg QY201 tablets or 20mg QY201 placebo,BID
• 5mg QY201 tablets,BID
5mg QY201 tablets,BID
• 10mg QY201 tablets,BID
10mg QY201 tablets,BID
• 20mg QY201 tablets,BID
20mg QY201 tablets,BID
• QY201 placebo,BID
QY201placebo,BID

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Treatment Emergent Adverse Events (AEs)- Phase ?b	Number of participants with treatment emergent adverse events (AEs) and change from baseline in vital signs (blood pressure, pulse rate, respiratory rate body temperature), physical examination, ECG parameters, clinical laboratory	From the first administration to 28 days after the last administration of the study drug
Primary	Percentage of Participants Achieving >=75% Improvement From Baseline in Eczema Area and Severity Index (EASI75) Response at Week 12- Phase ?	EASI quantifies severity of AD based on severity of lesion clinical signs and percentage (%) of body surface area (BSA) affected. Severity of clinical signs of AD lesions (erythema, induration/papulation, excoriation and lichenification) were scored separately for each of 4 body regions (head and neck, upper limbs, trunk and lower limbs ) on a 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based on % BSA with AD in body region: 0 (0%), 1 (0 to 9%), 2 (10 to 29%), 3 (30 to 49%), 4 (50 to 69%), 5 (70 to 89%) and 6 (90 to 100%). Total EASI score =0.1*Ah*(Eh+Ih+Exh+Lh) + 0.2*Au*(Eu+Iu+ExU+Lu) + 0.3*At*(Et+It+Ext+Lt) + 0.4*Al*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, with higher scores indicating greater severity of AD.	Week 12
Secondary	Pharmacokinetic parameters-Phase Ib	Tmax	Day1 to Day 30
Secondary	Pharmacokinetic parameters-Phase Ib	Cmax	Day1 to Day 30
Secondary	Pharmacokinetic parameters-Phase Ib	t1/2	Day1 to Day 30
Secondary	Pharmacokinetic parameters-Phase Ib	AUC0-t	Day1 to Day 30
Secondary	Pharmacokinetic parameters-Phase Ib	CL/F	Day1 to Day 30
Secondary	Pharmacokinetic parameters-Phase Ib	Vz/F	Day1 to Day 30
Secondary	Percentage of Participants Achieving >=50%/75%/90% Improvement From Baseline in Eczema Area and Severity Index (EASI-50/EASI-75/EASI-90) Response at Week 2 and 4	EASI quantifies severity of AD based on severity of lesion clinical signs and percentage (%) of body surface area (BSA) affected. Severity of clinical signs of AD lesions (erythema, induration/papulation, excoriation and lichenification) were scored separately for each of 4 body regions (head and neck, upper limbs, trunk and lower limbs ) on a 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based on % BSA with AD in body region: 0 (0%), 1 (0 to 9%), 2 (10 to 29%), 3 (30 to 49%), 4 (50 to 69%), 5 (70 to 89%) and 6 (90 to 100%). Total EASI score =0.1*Ah*(Eh+Ih+Exh+Lh) + 0.2*Au*(Eu+Iu+ExU+Lu) + 0.3*At*(Et+It+Ext+Lt) + 0.4*Al*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, with higher scores indicating greater severity of AD.	Week 2 and 4
Secondary	Number of Participants With Treatment Emergent Adverse Events (AEs)- Phase ?	Number of participants with treatment emergent adverse events (AEs) and change from baseline in vital signs (blood pressure, pulse rate, respiratory rate body temperature), physical examination, ECG parameters, clinical laboratory	From the first administration to 28 days after the last administration of the study drug